BASF Pharma Ingredients and Services - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

BASF Pharma Ingredients and Services


Soluplus® — the solid solution — is an innovative excipient that enables new levels of solubility and bioavailability for poorly soluble active ingredients. Developed specifically for solid solutions, this easy-to-process polymer produces a significant improvement in API release.

Thanks to its high flowability and excellent extrudability, Soluplus® exhibits superior performance in forming solid solutions, especially in hot-melt extrusion processes. These solid solutions make the active pharmaceutical ingredient available in a dissolved state, leading to improved bioavailability once in the body. As a result, the polymer is opening new doors in the research and development of innovative pharmaceuticals.

Soluplus® is not limited to solid solutions formed via hot-melt extrusion, but can also be used as a matrix former in spray-drying processes. In addition, it can be deployed as a binder in wet or dry granulation and in drug layering.

A wide range of toxicological studies have been performed on Soluplus®, and the safety of the product has been comprehensively documented.

BASF Pharma Ingredients and Services
www.soluplus.com
pharma-ingredients@basf.com

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerTargeting Different Off-Shore Destinations
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAsymmetric Synthesis Continues to Advance
Jill Wechsler Regulatory Watch Jill Wechsler Data Integrity Key to GMP Compliance
Sean Milmo European Regulatory WatchSean MilmoExtending the Scope of Pharmacovigilance Comes at a Price
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes

Click here